Trans-synaptic tau spreading and propagation mechanisms in AD
This hypothesis addresses a mechanistically compelling and therapeutically relevant target in neurodegeneration. TREM2 represents one of the strongest genetic risk factors for Alzheimer's disease identified in the past decade, and the proposed mechanism connecting TREM2 signaling to tau clearance has substantial biological plausibility. However, several contextual factors and knowledge gaps warrant careful consideration before advancing therapeutic strategies.
---
The hypothesis is substantially strengthened by human genetic evidence linking TREM2 to neurodegeneration risk:
- R47H variant (TREM2): Confers ~2-4-fold increased risk for Alzheimer's disease (Guerreiro et al., 2013; Jonsson et al., 2013). This variant specifically impairs TREM2's ability to bind lipid ligands and apolipoprotein E, directly supporting the receptor's functional importance in CNS homeostasis
The hypothesis presents TREM2 as directly orchestrating tau clearance, but the actual ligand-receptor pairing remains unestablished. TREM2 binds diverse structures including phospholipids, lipoproteins, ApoE, and myelin debris—with remarkably low specificity. The proposed mechanism implicitly assumes tau itself (or tau-containing debris) serves as the relevant TREM2 ligand during neurodegeneration, yet direct binding studies demonstrating tau-TREM2 interaction are notably absent from the literature. Alternative interpretations deserve equal consideration:
- TREM2 may respond to secondary signals: Microglia could be clearing tau-containing cellular debris (from dying neurons) rather than soluble/extracellular tau directly. TREM2 might recognize lipid signatures or ApoE-tau complexes rather than tau itself.
- ApoE-dependent mechanisms: TREM2's established interaction with ApoE-lipoprotein particles may be the operative pathway, with tau as a coincidental passenger rather than the primary substrate.
- Temporal disconnect: The mechanistic narrative assumes TREM2 activation and tau clearance occur contemporaneously, but phagocytosis of extracellular tau species may represent a downstream consequence of earlier TREM2-dependent responses (metabolic reprogramming, survival signaling) rather than a direct effector function.
The hypothesis explicitly targets "extracellular tau species," but this represents a small fraction of total tau pathology in Alzheimer's disease. Neurofibrillary tangles are predominantly
The hypothesis proposes that pharmacological activation of TREM2 on microglia will enhance clearance of extracellular tau aggregates, potentially slowing neurodegeneration in tauopathies such as Alzheimer's disease. The mechanism involves TREM2/DAP12 signaling, which promotes actin reorganization, phagocytic receptor expression, and lysosomal biogenesis—all supporting a neuroprotective microglial response.
---
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Plausibility | 0.72 | TREM2 signaling cascade is well-characterized; connection to phagocytosis documented. Critical gap: Direct tau-TREM2 binding has not been demonstrated. |
| Evidence Strength | 0.75 | Strong human genetics (R47H, loss-of-function variants); solid mouse model data linking TREM2 to tau pathology phenotypes; weak direct evidence for the specific extracellular tau phagocytosis mechanism. |
| Novelty | 0.55 | TREM2 as a therapeutic target is well-explored; multiple antibodies in development; the specific tau-clearance angle offers moderate incremental novelty. |
| Feasibility | 0.70 | Downstream readouts (phagocytosis, signaling markers) are measurable; distinguishing tau-specific effects